Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Janux Therapeutics, Inc. - Common Stock (NQ: JANX )

46.76 -4.06 (-7.99%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,112,811
Open 50.78
Bid (Size) 46.76 (2)
Ask (Size) 49.85 (1)
Prev. Close 50.82
Today's Range 42.58 - 50.89
52wk Range 7.790 - 71.71
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The Top 5 Mid Cap Stocks Of 2024
These high-fliers are on the leading edge of innovation. 
Via Talk Markets
Topics Stocks / Equities
Navigating 10 Analyst Ratings For Janux Therapeutics
Via Benzinga

Performance

YTD
-12.17%
-12.17%
1 Month
-23.97%
-23.97%
3 Month
-5.25%
-5.25%
6 Month
+7.57%
+7.57%
1 Year
+360.69%
+360.69%

More News

Read More
SoundHound, Asana And Victorias Secret Are Among Top 10 Mid Cap Gainers Last Week (Dec 2-Dec 6): Are The Others In Your Portfolio?
Via Benzinga
Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters’ Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million
From Janux Therapeutics
Via Business Wire
Why Janux Therapeutics Crushed the Market Today
Via The Motley Fool
Evaluating Janux Therapeutics: Insights From 6 Financial Analysts
Via Benzinga
Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
From Janux Therapeutics
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Janux Therapeutics Announces Proposed Public Offering
From Janux Therapeutics
Via Business Wire
Cracking The Code: Understanding Analyst Reviews For Janux Therapeutics
Via Benzinga
Navigating 5 Analyst Ratings For Janux Therapeutics
Via Benzinga
S&P 500 Cools From Post-Election Record Highs
Via Talk Markets
Topics Stocks Stocks / Equities
Exposures US Equities
Janux Therapeutics' Prostate Cancer Trial Data Exceeds Investor Expectations: Analyst
Via Benzinga
AT&T Updates 2024 Outlook, Joins ZJK Industrial, Janux Therapeutics, Credo Technology Group And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Janux, Vir Catapult On 'Unprecedented' Results In Prostate Cancer Patients
Via Investor's Business Daily
Why Credo Technology Group Shares Are Trading Higher By 40%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Analyst Expectations For Janux Therapeutics's Future
Via Benzinga
Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC
From Janux Therapeutics
Via Business Wire
Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data in Phase 1a Dose Escalation for JANX007 in mCRPC and Doses Selected for Phase 1b Expansion Studies
From Janux Therapeutics
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
From Janux Therapeutics
Via Business Wire
JANX Stock Earnings: Janux Therapeutics Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
From Janux Therapeutics
Via Business Wire
Janux Therapeutics Announces Updates to Board of Directors
From Janux Therapeutics
Via Business Wire
GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.